News Summary
In 2025, the ALS community witnessed unprecedented advancements in research, treatment, and advocacy. Key developments included promising drug trials, such as Qalsody and NUZ-001, early diagnostic tools, and significant policy changes for veterans with ALS. Advocacy efforts surged, with increased funding for research and public awareness campaigns led by influential figures. The collective achievements highlight a hopeful path forward in the fight against ALS.
Nationwide – The year 2025 marked a period of significant progress and renewed hope for the amyotrophic lateral sclerosis (ALS) community, with major advancements in research, treatment development, and patient advocacy. A comprehensive review of the year’s top stories highlights critical breakthroughs, including the FDA’s breakthrough designation for a device aimed at slowing disease progression, promising results from drug trials like Qalsody and NUZ-001, and heightened public awareness driven by prominent advocates.
Research Breakthroughs and Promising Treatments
Throughout 2025, several research initiatives brought the scientific community closer to understanding and effectively treating ALS. One of the most significant developments was a new study by researchers at the Washington University School of Medicine in St. Louis which reported that the long-term use of Qalsody (tofersen), an FDA-approved drug for a specific genetic form of ALS (SOD1-ALS), showed the ability to delay symptom progression and death. The study indicated that approximately one-quarter of participants experienced stabilization or even improvement in their condition over three to five years, a previously unheard-of outcome in this form of the disease. Qalsody works by targeting and reducing the production of the mutated SOD1 protein. This drug, developed by Biogen and Ionis Pharmaceuticals, continues to be studied, including in the ATLAS trial for pre-symptomatic SOD1-ALS individuals.
Another notable advance involved the investigational oral therapy NUZ-001, a repurposed veterinary medication, which demonstrated a significantly slower disease progression and prolonged survival in a subset of patients during an extension of a Phase 1 clinical trial. Patients treated with NUZ-001 showed a 31% slower functional decline, a 43% slower decline in lung function, and a 77% lower risk of death compared to historical controls. NUZ-001 has now been cleared by the FDA to join the HEALEY ALS platform trial, becoming the ninth compound to be included in this significant research initiative.
Further innovation came from a personalized antisense oligonucleotide (ASO) drug therapy targeting CHCHD10 mutations, which showed remarkable efficacy in clinical trials by reducing ALS progression by over 50%. This breakthrough represents a highly targeted genetic mechanism, offering a new approach to treatment. Additionally, new analyses of data from two Phase 2 clinical trials revealed that Neuvivo’s treatment candidate NP001 (sodium chlorite) was associated with a substantial survival benefit among a subset of patients who did not show signs of disease progression, living 22 months longer than a control group. A pivotal Phase 3 trial for NP001 is anticipated.
Diagnostic Advances and Disease Understanding
Beyond treatments, 2025 brought significant strides in early diagnosis. Researchers developed a highly accurate blood test based on a unique protein signature that may enable the diagnosis of ALS up to a decade before the onset of the first symptoms. Earlier diagnosis is crucial as it could facilitate earlier intervention and enrollment in clinical trials, potentially leading to improved patient outcomes.
Understanding the disease’s underlying mechanisms also saw progress. New evidence hinted at an autoimmune component in ALS, with U.S. researchers identifying an immune response mistakenly targeting the C9ORF72 protein. This finding could influence future treatment strategies, particularly if ALS is, in part, an autoimmune disease. Additionally, an Emory University study offered answers as to why a promising ALS drug failed, contributing valuable insights into the complexities of drug development for the condition.
Advocacy and Patient Support
Patient advocacy and support also saw a significant boost in 2025. Actor Eric Dane, who is living with an ALS diagnosis, joined the board of directors of Target ALS, a U.S.-based nonprofit that funds research to find new treatments. Dane became a public advocate, portraying a character with ALS on a television drama and co-leading Target ALS’s “Ending ALS Starts with You” campaign, which aims to raise $500,000 for research by year-end. This initiative underscores the critical role of public figures in raising awareness and funding for ALS research.
In terms of policy, the Elizabeth Dole 21st Century Veterans Healthcare and Benefits Improvement Act was signed into law on January 2, 2025, to improve access to in-home care for veterans with ALS. This legislation ensures that the Department of Veterans Affairs will cover up to 100% of home care costs, making it more accessible for veterans, who are twice as likely to develop ALS as non-veterans. Furthermore, state-level advocacy efforts by the ALS Association led to increased funding for ALS care and research, with appropriations doubling to nearly $14 million nationwide since 2022. States like California, Florida, and Massachusetts increased funding, and Oklahoma took a step towards a potential $1 million investment in ALS care services. New legislation in Texas and Nevada also expanded access to affordable Medigap plans for people under 65 with ALS.
Technological Innovations
Technological advancements also played a crucial role. An experimental, noninvasive device for slowing the progression of functional symptoms in people with ALS received FDA breakthrough device designation. This neuromodulation device, called MyoRegulator from Pathmaker Neurosystems, aims to reduce excessive nerve cell activation, and its approach is being supported by ongoing clinical trials.
The Path Forward
The collective efforts in 2025, encompassing rigorous scientific investigation, the development of potential therapies, improved diagnostic tools, and robust advocacy, underscore a determined global commitment to combating ALS. As the community looks towards 2026, the momentum generated by these significant advancements provides a foundation for continued progress in the quest for effective treatments and, ultimately, a cure for this debilitating disease.
Frequently Asked Questions
- What were some major ALS treatment breakthroughs in 2025?
- In 2025, significant treatment breakthroughs included the long-term use of Qalsody (tofersen) showing delayed symptom progression and death in SOD1-ALS patients, and the investigational oral therapy NUZ-001 demonstrating slower disease progression and prolonged survival.
- Was there a new diagnostic tool for ALS developed in 2025?
- Yes, researchers developed a highly accurate blood test in 2025 that may enable the diagnosis of ALS up to a decade before the onset of the first symptoms.
- How did advocacy efforts impact ALS in 2025?
- Advocacy efforts in 2025 led to increased public awareness, partly due to actor Eric Dane joining the Target ALS board and launching a campaign. Policy-wise, the Elizabeth Dole 21st Century Veterans Healthcare and Benefits Improvement Act was signed, improving in-home care access for veterans with ALS. State-level funding for ALS care and research also nearly doubled nationwide since 2022.
- What new device received FDA breakthrough status for ALS in 2025?
- An experimental, noninvasive device called MyoRegulator from Pathmaker Neurosystems received FDA breakthrough device designation in 2025, aimed at slowing the progression of functional symptoms in people with ALS.
- What new insights were gained into the causes of ALS in 2025?
- In 2025, new evidence hinted that ALS may have an autoimmune component, with U.S. researchers identifying an immune response mistakenly targeting the C9ORF72 protein. An Emory University study also provided answers as to why a promising ALS drug failed.
Key Features of ALS Progress in 2025
| Feature | Description | Scope |
|---|---|---|
| Qalsody (tofersen) Outcomes | Long-term use showed delayed symptom progression, reduced death risk, and stabilization/improvement in 25% of SOD1-ALS patients. | Nationwide |
| NUZ-001 Therapy | Investigational oral therapy demonstrated slower disease progression (31% functional, 43% lung) and prolonged survival (77% lower death risk) in trials; cleared for HEALEY ALS platform. | Nationwide |
| Blood Test for Early Diagnosis | Developed to diagnose ALS up to 10 years before symptom onset, based on a unique protein signature. | Nationwide |
| MyoRegulator Device | Noninvasive neuromodulation device from Pathmaker Neurosystems received FDA breakthrough designation for slowing functional symptom progression. | Nationwide |
| Eric Dane Advocacy | Actor Eric Dane joined Target ALS board and co-led a campaign to raise $500,000 for research, increasing public awareness. | Nationwide |
| Elizabeth Dole Act | Legislation signed to cover up to 100% of in-home care costs for veterans with ALS, effective January 2, 2025. | Nationwide |
| State-Level ALS Funding | State appropriations for ALS-focused programs nearly doubled to $14 million nationwide since 2022, with increases in California, Florida, Massachusetts, and potential for Oklahoma. | State-level |
| ALS Autoimmune Component | New evidence suggested an immune response targeting the C9ORF72 protein, hinting at an autoimmune component in ALS. | Nationwide |
| CHCHD10 Mutation ASO Drug | Personalized antisense oligonucleotide drug therapy targeting CHCHD10 mutations showed over 50% reduction in ALS progression in clinical trials. | Nationwide |
Deeper Dive: News & Info About This Topic
Accelerating Genomic Healthcare Through Patient Advocacy
2025 EndoRISE Fall Forum Accelerates Endometriosis Research
Patient Advocates for Early Detection in Lung Cancer
Two Families Revolutionize Rare Disease Advocacy in Massachusetts
St. Louis Couple Advocates for Lung Cancer Awareness and Early Detection